Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — 121 Tech Investment Conference, Singapore 2018
20 slides from Clever Culture Systems's conference presentation, Dec 3, 2018
Slide 1: LBT Presentation – 121 Tech Investment Conference, Singapore
LBT PRESENTATION - 121 TECH INVESTMENT CONFERENCE, SINGAPORE Adelaide, Australia, 3 December 2018: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence is pleased to announce the Company
Slide 2: Company Update
Company Update 121 Tech Investment Conference, Singapore Brent Barnes Managing Director & Chief Executive Officer 4th December 2018 ASX code: LBT lbtinnovations.com
Slide 3: Disclaimer
Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Giv
Slide 4: Customer problems: Microbiology labs
Customer problems: Microbiology labs 70% 85% 12% 9% High Demand Inefficient resource Inconsistent results Qualified utilisation microbiologists 70% of clinical Up to 85% of plates Variability in plate 9%3 vacancy rate in the US. decisions are based read are negative or reading with error Average age
Slide 5: Solution: APAS® Independence
Solution: APAS® Independence The first and only automated culture plate reader. Automated imaging, analysis and interpretation of agar culture. Powered by AI. Slide No. 4 © LBT Innovations 2018
Slide 6: Clinically Proven Technology
Clinically Proven Technology Scientific publication Customer publication 10,000 patient clinical trial “APAS® Independence facilitated operational efficiencies in both specimen processing and culture reading” APAS® technology US FDA cleared as class II medical device Slide No. 5 © LBT Innovations 20
Slide 7: Corporate Snapshot – ASX.LBT
Corporate Snapshot – ASX.LBT Key Statistics as at 29 Nov 2018 Financials • $7.9m raised May18 - LBT well funded Current Price $0.09 per share • Cash 30-Sep-18 ~$5.3m, ~$6m additional funding available 12 month range $0.09 - $0.27 • Focus on early commercial launch & global footprint Shares Outstandi
Slide 8: Australia: Launch Market
Australia: Launch Market • Positive market feedback • Pipeline sales targets identified, exact sales timing difficult to predict, sales cycle 6 – First global sale 12+ months August 2018 • Multiple opportunities in pipeline Channel 7 Melbourne, Sunday 8th October 2017 https://www.facebook.com/7NewsM
Slide 9: Strategic placements: centre of excellence
Strategic placements: centre of excellence DE: Sales Executive Labor Dr Wisplinghoff Dec-18 Cologne, Germany St Vincent’s Hospital Melbourne, Australia Hennepin Health System Minneapolis, USA AU: Sales Executive Apr-18 Slide No. 8 © LBT Innovations 2018
Slide 10: Attractive Revenue Model
Attractive Revenue Model Customer: Pathology laboratories 50:50 Joint Venture 5 year revenue opportunity Profits and costs shared ~USD$0.45m per instrument $$ Instrument USD$300,000 *Distributor Margin Regional Distributors(s) Annual software license $$ $$ Legal manufacturer of USD$30K *20% - 40% ma
Slide 11: Sales forecast: similar products case study
Sales forecast: similar products case study Units placed MALDI-TOF: launched 2004 Case Study APAS® globally MALDI-TOF: ~1500 units Previ Isola: launched 2009 placed after 10 years Independence: ~12% global 1,500 penetration 1,500 units after 10 years 2 Manufacturers: 700 units placed in US Bruker &
Slide 12: Large Market Opportunity
Large Market Opportunity Macro Analysis Supporting Sales Validating the opportunity ~13,000 labs Customer payback target: 2.5 – 3.5 yrs Over 160 labs, finalised H2CY18: Australia, UK, Germany, USA Feedback that influences customer interest and sales: ✓ Media Used – brand and product codes. High acce
Slide 13: Competitor Landscape
Competitor Landscape 1st & only FDA No direct cleared technology competitor Modular & simple Affordable installation APAS® Independence Inoculation and Culture Automated Plate Identification & antibiotic Incubate Plate Streaking Reading sensitivity testing Competition snapshot: Existing automation t
Slide 14: Innovating AI and intelligent imaging for the future of healthcare
Innovating AI and intelligent imaging for the future of healthcare Slide No. 13 © LBT Innovations 2018
Slide 15: Future: Building Strategic Capability
Future: Building Strategic Capability Transitioning from outsourced development to internal capability. Critical to develop future analysis modules Our Values: APAS Development History (outsourced) • People investment: Artificial intelligence, software engineering, science. Unique value proposition.
Slide 16: Extension of APAS Algorithm
Extension of APAS Algorithm Antibiotic Sensitivity Testing Analysis Gram Stain Reading Histopathology Digital Pathology APAS® automated Automated Slide Scanning detection WoundVue Slide No. 15 © LBT Innovations 2018
Slide 17: Broader APAS® Opportunities
Broader APAS® Opportunities LBT’s proven artificial intelligence capability and experience means we are well placed to grow through partnerships / acquisition to extend the application into new clinical disciplines. LBT end-to-end workflow delivery with focus on customer benefits Data Data Treatment
Slide 18: Outlook
Outlook Submit 510(k) for APAS Independence (update to be 2019 Regulatory given by 31-Dec-18) FDA clearance Present publications • ECCMID • ASM Market Development Expand reference sites Analysis module development Develop international sales pipeline, leading to local distributor(s) placement Sales
Slide 19: Brent Barnes
Brent Barnes Managing Director & CEO Level 8, 44 Waymouth Street Adelaide SA 5000 +61 (0)8 8227 1555 info@lbtinnovations.com lbtinnovations.com
Slide 20: Experienced Board of Directors
Experienced Board of Directors Brent Barnes Managing Director Commenced Oct-16 Kate Costello Steve Mathwin Chairman NED Experience • Prior to LBT, executive working for #1 cochlear implant global medical device company, Cochlear Limited (ASX:COH) • Lived in United States (Colorado and Texas) – estab
Clever Culture Systems — 121 Tech Investment Conference, Singapore 2018 on 6ix